VCYT:NSD-Veracyte Inc.

EQUITY | Biotechnology | NASDAQ Global Market

Last Closing

USD 28.51

Change

-0.05 (-0.18)%

Market Cap

USD 0.21B

Volume

0.48M

Analyst Target

USD 27.67
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Veracyte Inc is engaged in the discovery, development and commercialization of molecular cytology solutions that enable physicians to make more informed treatment decisions at an early stage in patient treatment.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-06-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+0.80 (+0.20%)

USD 107.38B
REGN Regeneron Pharmaceuticals Inc

+2.83 (+0.32%)

USD 106.98B
MRNA Moderna Inc

-0.59 (-0.58%)

USD 39.68B
BNTX BioNTech SE

+0.64 (+0.74%)

USD 21.93B
ARGX argenx NV ADR

+1.82 (+0.51%)

USD 21.64B
GMAB Genmab AS

+0.37 (+1.31%)

USD 19.78B
ALNY Alnylam Pharmaceuticals Inc

-0.75 (-0.52%)

USD 18.36B
RPRX Royalty Pharma Plc

+0.27 (+0.97%)

USD 18.18B
BGNE BeiGene Ltd

-2.44 (-1.85%)

USD 16.99B
BMRN Biomarin Pharmaceutical Inc

-1.44 (-1.60%)

USD 16.06B

ETFs Containing VCYT

WDNA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 126.63% 94% A 98% N/A
Dividend Return N/A N/A N/A N/A F
Total Return 126.63% 94% A 98% N/A
Trailing 12 Months  
Capital Gain 232.67% 99% N/A 99% N/A
Dividend Return N/A N/A N/A N/A F
Total Return 232.67% 99% N/A 99% N/A
Trailing 5 Years  
Capital Gain 90.83% 80% B- 79% B-
Dividend Return N/A N/A N/A N/A F
Total Return 90.83% 79% B- 77% C+
Average Annual (5 Year Horizon)  
Capital Gain 31.18% 81% B- 88% B+
Dividend Return 31.18% 81% B- 88% B+
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 87.25% 19% F 7% C-
Risk Adjusted Return 35.73% 75% C 52% F
Market Capitalization 0.21B 84% B 74% C

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -43.86 95% 93%
Price/Book Ratio 14.70 9% 6%
Price / Cash Flow Ratio -17.60 97% 96%
Price/Free Cash Flow Ratio -66.30 97% 94%
Management Effectiveness  
Return on Equity -42.79% 63% 22%
Return on Invested Capital -28.30% 77% 28%
Return on Assets -24.44% 78% 24%
Debt to Equity Ratio 61.50% 20% 41%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.